Company Overview of Zyngenia, Inc.

Snapshot

People

Overview Board Members Committees

Executive Profile

David R. Parkinson M.D.

Interim Chief Medical Officer, Chairman of The Clinical Advisory Board and Director, Zyngenia, Inc.

Age	Total Calculated Compensation	This person is connected to 5 Board Members in 5 different organizations across 10 different industries. See Board Relationships
62	--

Background

Dr. David R. Parkinson, M.D. serves as Interim Chief Medical Officer at Zyngenia, Inc. Dr. Parkinson has been a Venture Partner at New Enterprise Associates since 2012. He served as the President and Chief Executive Officer of Nodality Inc. from September 24, 2007 to 2012. Prior to 2007, he served as Senior Vice President of Oncology Research and Development at Biogen Idec Inc., since March 29, 2006. At Biogen Idec, he oversaw all oncology discovery research efforts ... and the development of the oncology pipeline. He served as Vice President of Oncology Development and Commercialization of Amgen Inc. since August 4, 2005. He served as Vice President and Head of the Clinical Oncology Therapeutic Area of Amgen Inc. since May 21, 2003. He directed global development efforts in oncology for all of Amgen's new product candidates and new indications for marketed products. Dr. Parkinson has a wealth of experience in drug development, and an international reputation in clinical oncology, including a track record in developing new therapies in oncology. He joined Amgen from Novartis Pharmaceutical Corporation where he was Global Head, Translational Development and a member of their Oncology Business Unit Executive Committee. He served as Vice President of global clinical oncology development at Novartis Corporation. As head of oncology clinical research and development at Novartis, he led teams that successfully registered numerous important new therapies, including Gleevec(TM), the first successful protein kinase inhibitor, and Zometa(R), a bisphosphonate indicated for the treatment of bone metastases. He serves as Chairman of The Clinical Advisory Board and Director at Zyngenia, Inc. He serves as a Director of Nodality Inc. He serves as a Member of Clinical Advisory Board of Onconova Therapeutics, Inc. He serves on the National Cancer Policy Forum of the Institute of Medicine and is a member of the FDA's Science Board. Dr. Parkinson has been a Director of Ambit Biosciences Corporation since April 2013 and Threshold Pharmaceuticals Inc. since May 12, 2010. He serves as a Director of the American Association of Cancer Research (AACR). He served as a Member of Clinical Advisory Board at CytRx Corporation since February 2008. He served as a Director of Abbott Biotherapeutics Corp. (Also known as Facet Biotech Corporation) since December 2008. He served as President of the International Society of Biological Therapy, and past Editor of the Journal of Immunotherapy. He worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program, before leaving for Novartis. After two years at the University of Texas M.D. Anderson Cancer Center, Dr. Parkinson joined the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute, where he also served as a member of the Biologics Evaluation Committee at the U.S. Food and Drug Administration. His skills in drug evaluation brought him to the attention of Novartis, where he occupied positions of increasing responsibility since 1997. He is the recipient of numerous honors and awards, including the Wiley Medal (Commissioner''s Citation of Merit) from the U.S. Food and Drug Administration in 1997, and teaching awards at both Tufts University and the University of Texas. He pursued clinical training at the Royal Victoria Hospital, McGill University, and at the New England Medical Center, where he was also an Assistant Professor at Tufts University School of Medicine, and an attending physician in hematology/oncology. Dr. Parkinson received his M D degree from the University of Toronto Faculty of Medicine in 1977, with Internal Medicine.

Read Full Background